Primary Sclerosing Cholangitis. A narrative review

被引:0
|
作者
Camilo Villa-Gomez, Cristian [1 ]
Stiven Velilla-Aguirre, Daniel [1 ]
Camila Lopera-Restrepo, Laura [1 ]
Ivan Hoyos-Duque, Sergio [2 ]
机构
[1] Univ Antioquia, Grp Gastrohepatol, Medellin, Colombia
[2] Univ Antioquia, Hosp Pablo Tobon Uribe, Unidad Hepatol & Trasplante Hepat, Fac Med,Grp Gastrohepatol, Medellin, Colombia
关键词
Cholangiocarcinoma; Cholangitis; Sclerosing; Cho-lestasis; Colorectal Neoplasms; Liver Transplantation; Ulcerative Colitis; PRIMARY BILIARY CHOLANGITIS; INFLAMMATORY-BOWEL-DISEASE; DOSE URSODEOXYCHOLIC ACID; LIVER-TRANSPLANTATION; ALKALINE-PHOSPHATASE; RISK-FACTORS; RECURRENCE; EPIDEMIOLOGY; METRONIDAZOLE; ASSOCIATION;
D O I
10.17533/udea.iatreia.57
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary sclerosing cholangitis (PSC) is a rare, chronic liver pathology characterized by inflammation and fibrosis of the bile ducts, whose evolution can lead to cirrhosis, portal hypertension and end-stage liver disease. Its etiology is unknown, but it has been related to genetic and autoinflammatory factors. In addition, it has a very close relationship with inflammatory bowel disease. Its clinical presentation is nonspecific, the main symptoms are pruritus and fatigue. The standard test for diagnosis is magnetic resonance cholangiopancreatography (MRCP), where an annular aspect is observed caused by short multifocal stenoses with alternating normal or dilated segments. Currently, there is no pharmacological treatment that can prolong the survival without liver transplantation in PSC. Symptomatic treatment is warranted, especially for pruritus. The only curative treatment that is currently available is liver transplantation, although there is a risk of recurrence of the disease. The monitoring of intestinal inflammatory disorders (IID), malignancy and metabolic bone disease in these patients is very important. It has been seen that some factors, such as early diagnosis, are good prognosis for the disease.
引用
收藏
页码:251 / 261
页数:11
相关论文
共 50 条
  • [11] Primary sclerosing cholangitis. Current diagnostics and treatment
    Liwinski, T.
    Schramm, C.
    INTERNIST, 2018, 59 (06): : 551 - 559
  • [12] Pancreatic histopathology in patients with primary sclerosing cholangitis.
    Knisely, AS
    Lee, RG
    LABORATORY INVESTIGATION, 1996, 74 (01) : 788 - 788
  • [13] Biliary intraductal neoplasia in primary sclerosing cholangitis.
    Erhlich, S
    Agoff, SN
    Bronner, MP
    Taylor, S
    MODERN PATHOLOGY, 2001, 14 (01) : 195A - 195A
  • [14] Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis.
    Ahrendt, SA
    Pitt, HA
    Nakeeb, A
    Klein, AS
    Lillemoe, KD
    Kalloo, AN
    Cameron, JL
    GASTROENTEROLOGY, 1998, 114 (04) : A1374 - A1374
  • [15] Effects of medical therapy in children with primary sclerosing cholangitis.
    Feldstein, AE
    Angulo, P
    Freese, DK
    El-Youssef, M
    Perrault, J
    HEPATOLOGY, 2002, 36 (04) : 494A - 494A
  • [16] Small Duct Primary Sclerosing Cholangitis. A Rare Entity
    Kumar, Vinod
    Shahani, Shobha
    Hammoud, Ihab
    INFLAMMATORY BOWEL DISEASES, 2016, 22 : S12 - S12
  • [17] Primary sclerosing cholangitis. A twelve-year experience
    Orellana, I
    Valera, JM
    Nei, C
    Poniachik, J
    Berger, Z
    Latorre, R
    Smok, G
    Brahm, J
    REVISTA MEDICA DE CHILE, 2005, 133 (07) : 776 - 780
  • [18] Prevalence and progression of bone disease in primary sclerosing cholangitis.
    Angulo, P
    Therneau, T
    Jorgensen, R
    Dickson, ER
    Lindor, KD
    GASTROENTEROLOGY, 1997, 112 (04) : A1213 - A1213
  • [19] Characterization of histone autoantibodies in patients with primary sclerosing cholangitis.
    Orth, T
    zumBuschenfelde, KHM
    Mayet, WJ
    HEPATOLOGY, 1997, 26 (04) : 1255 - 1255
  • [20] ERCP associated complications in patients with primary sclerosing cholangitis.
    Eng, SC
    Lee, SD
    Kimmey, MB
    Tung, BY
    Saunders, MD
    Kowdley, KV
    HEPATOLOGY, 2001, 34 (04) : 524A - 524A